Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erick Gamelin

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2011
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patientsNicolas Azzopardi, Thierry Lecomte, David Ternant, et al.
Oncotarget|January 8, 2015
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1Barbara Jonchère, Alexandra Vétillard, Bertrand Toutain, et al.
American Journal of Clinical Oncology|June 7, 2006
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancerHugues Bourgeois, Aurélie Ferru, Alain Lortholary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le CancerMichel Ducreux, Marc Ychou, Agnès Laplanche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell CarcinomaJames Brugarolas, Gregory Obara, Kathryn E Beckermann, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
Blood|September 13, 2007
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cellsDorothée Duluc, Yves Delneste, Fang Tan, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
Seminars in Oncology|April 12, 2017
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensificationMichèle Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2011
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patientsNicolas Azzopardi, Thierry Lecomte, David Ternant, et al.
Oncotarget|January 8, 2015
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1Barbara Jonchère, Alexandra Vétillard, Bertrand Toutain, et al.
American Journal of Clinical Oncology|June 7, 2006
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancerHugues Bourgeois, Aurélie Ferru, Alain Lortholary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le CancerMichel Ducreux, Marc Ychou, Agnès Laplanche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell CarcinomaJames Brugarolas, Gregory Obara, Kathryn E Beckermann, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
Blood|September 13, 2007
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cellsDorothée Duluc, Yves Delneste, Fang Tan, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
Seminars in Oncology|April 12, 2017
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensificationMichèle Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, et al.
Pageof 5